Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Quarterly results
Appointed director
CC transcript
Acq. announced
Director departure
NOVAVAX INC (NVAX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights"
05/09/2023 8-K Quarterly results
Docs: "Novavax Reports First Quarter 2023 Financial Results and Operational Highlights",
"Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccines Demonstrate Robust Immune Responses"
11/08/2022 8-K Quarterly results
Docs: "Three Months Ended September 30, 2022 2021 Revenue: Product sales $ 626,091 $ -- Grants 106,273 135,007 Royalties and other 2,213 43,837 Total revenue 734,577 178,844 Expenses: Cost of sales 434,593 -- Research and development 304,297 408,195 Selling, general, and administrative 122,876 77,793 Total expenses 861,766 485,988 Income from operations Other income : Interest income Other income Income before income tax expense Income tax expense 2,472 6,041 Net income $ $ Net income per share Basic and diluted $ $ Weighted average number of common shares outstanding Basic and diluted 78,274 74,745 7 SELECTED CONSOLIDATED BALANCE SHEET DATA September 30, 2022 December 31, 2021 Cash and cash equivalents $ 1,280,581 $ 1,515,116 Total restricted cash 12,441 13,143 Total current assets 1,759,965..."
08/09/2022 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights"
05/10/2022 8-K Quarterly results
11/05/2021 8-K Quarterly results
Docs: "Novavax Reports Third Quarter 2021 Financial Results and Operational Highlights"
08/06/2021 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights"
05/11/2021 8-K Quarterly results
05/12/2020 8-K Quarterly results
11/08/2019 8-K Quarterly results
Docs: "Novavax Reports Third Quarter 2019 Financial Results"
08/08/2019 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2019 Financial Results"
05/03/2019 8-K Quarterly results
Docs: "Novavax Reports First Quarter 2019 Financial Results"
11/08/2018 8-K Quarterly results
Docs: "Novavax Reports Third Quarter 2018 Financial Results"
08/09/2018 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2018 Financial Results"
05/10/2018 8-K Quarterly results
Docs: "Novavax Reports First Quarter 2018 Financial Results"
03/15/2018 8-K Quarterly results
Docs: "Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results",
"Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer"
11/07/2017 8-K Quarterly results
Docs: "Novavax Reports Third Quarter 2017 Financial Results"
08/09/2017 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2017 Financial Results"
05/09/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
11/14/2016 8-K Investor presentation, Quarterly results
Docs: "Novavax Reports Third Quarter 2016 Financial Results",
"Investor Presentation of Novavax, Inc"
08/10/2016 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2016 Financial Results"
05/05/2016 8-K Quarterly results
Docs: "Novavax Reports First Quarter 2016 Financial Results"
03/01/2016 8-K Quarterly results
Docs: "Novavax Reports Fourth Quarter and Year-End 2015 Financial Results"
11/09/2015 8-K Quarterly results
Docs: "Novavax Reports Third Quarter 2015 Financial Results Gaithersburg, Md., November 9, 2015 – Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the third quarter and nine months ended September 30, 2015. Novavax Third Quarter and Subsequent Achievements · Announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate in older adults . The vaccine was well-tolerated and fulfilled the Company's expectations on the primary, secondary and exploratory objectives of the trial. The trial is the first to demonstrate efficacy of an active RSV immunization in any clinical trial popul..."
08/11/2015 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2015 Financial Results Gaithersburg, Md., August 10, 2015 – Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the second quarter and six months ended June 30, 2015. Novavax Second Quarter and Subsequent Achievements: · Announced positive top-line data from a Phase 2 trial of its RSV F-protein nanoparticle vaccine candidate in older adults. The trial demonstrated statistically significant vaccine efficacy in the prevention of symptomatic RSV disease in older adults, the first vaccine to demonstrate efficacy against RSV disease in any population. The trial detected an attack rate of 4.9% for symptomatic R..."
05/08/2015 8-K Quarterly results
Docs: "Novavax Reports First Quarter 2015 Financial Results Gaithersburg, Md., May 7, 2015 – Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the first quarter 2015. Corporate Highlights First Quarter and Subsequent Achievements:"
02/27/2015 8-K Quarterly results
Docs: "Novavax Reports Fourth Quarter and Year-End 2014 Financial Results"
11/06/2014 8-K Quarterly results
Docs: "Novavax Reports Third Quarter 2014 Financial Results"
08/07/2014 8-K Quarterly results
Docs: "Novavax Reports Second-Quarter 2014 Financial Results"
05/08/2014 8-K Quarterly results
Docs: "Novavax Reports First-Quarter 2014 Financial Results"
03/14/2014 8-K Quarterly results
Docs: "Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of its H7N9 Avian Influenza VLP Vaccine Candidate with Matrix-M &trade"
05/07/2013 8-K Form 8-K - Current report
08/08/2012 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy